Scientists develop new basis for H5N1 vaccine: WHO

By Laura MacInnis

GENEVA (Reuters) - Scientists have used bird flu virus samples from Egypt to develop a new basis for a vaccine against the toxic H5N1 strain that continues to circulate, the World Health Organization said on Thursday.

Avian influenza kills about half the people it infects, but unlike the quickly circulating H1N1 flu virus has not been shown to pass easily between humans to date.

The WHO said the candidate virus was developed at the U.S. Centers for Disease Control and Prevention in Atlanta "thanks to the ministry of health and population of Egypt, for providing virus specimens,"

"This recombinant vaccine virus is available for distribution," it said in a statement on its website.

"Institutions, companies and others interested in pandemic vaccine development who wish to receive these candidate vaccine viruses should contact either the WHO Global Influenza Program ... or the Centers for Disease Control and Prevention."

Pharmaceutical companies including Novartis are already working on vaccines against H5N1 bird flu, which has killed or forced the culling of more than 300 million birds since 2003 as it spread to 61 countries in Asia, the Middle East and Africa.

While eclipsed on the headlines by the highly contagious H1N1 strain, which proved deadly in its North American epicenter but has caused mild symptoms as it spread, the WHO stressed it was important to remember the risks posed by avian influenza.

The U.N.'s Food and Agriculture Organization reported 250 outbreaks of H5N1 in birds in February alone -- in Bangladesh, China, Egypt, India, Indonesia, Laos, Nepal and Vietnam.